No. of cycles | Age (y) | Gleason score | PSA decline | % PSA change | PSMA PET before therapy | PSMA PET after last cycle | Bone scan | Reason for progression | Decision |
6 | 83 | 9 | Yes | −92.4 | PET ≤ bone scan | PR | SD | Follow-up | |
6 | 66 | 7 | No | 21.4 | PET > bone scan | PD | PR | B | Enzalutamide |
3 | 76 | 9 | No | 48.5 | PET > bone scan | PD | SD | A | 177Lu-PSMA |
3 | 66 | 9 | No | 25 | PET > bone scan | PD | PD | A | 177Lu-PSMA |
6 | 64 | 9 | Yes | −56 | PET ≤ bone scan | PR | SD | Follow-up | |
6 | 75 | Unknown | No | >100 | PET > bone scan | PD | PD | A | Chemotherapy |
6 | 73 | Unknown | No | 16 | PET ≤ bone scan | PD* | PR | B | Enzalutamide |
6 | 67 | 10 | No | 58 | PET ≤ bone scan | PD | PD | A | 177Lu-PSMA |
6 | 74 | 7 | No | >100 | PET > bone scan | PD | PD | A | Enzalutamide |
6 | 81 | 6 | No | 27 | PET ≤ bone scan | SD | SD | Chemotherapy | |
6 | 74 | 8 | No | >100 | PET ≤ bone scan | PD | SD | B | Chemotherapy |
6 | 73 | 8 | Yes | −58 | PET > bone scan | PR | PR | Follow-up | |
6 | 76 | 7 | Yes | −10 | PET ≤ bone scan | PR | PR | Follow-up |
↵* Bone metastases were in concordance with bone scintigraphy and PSMA regression; however, because of development of local recurrence, PET scan was reported as progressive disease.
PR = partial response; SD = stable disease; PD = progressive disease; B = only progression of soft-tissue metastases; A = progression of both bony and soft-tissue metastases.